Trending Now - RFK Jr. Advocates for Reinstating Controversial Peptides

WHO:

Ars Technica - Robert F. Kennedy Jr. (RFK Jr.) is advocating for the use of certain peptides.

Gizmodo - The FDA is involved in the decision to potentially unban these peptides.

WHAT:

The Guardian - Robert F. Kennedy Jr. stated he will approve the sale of “about 14” injectable peptide drugs to the public.

Ars Technica - The FDA is reportedly planning to allow the production of 14 previously banned peptides.

Gizmodo - More than a dozen peptides are expected to be removed from a list that prohibits compounding pharmacies from producing them.

WHEN:

Ars Technica - The FDA's decision is anticipated in 2026.

WHY:

The Guardian - Experts warn against the unapproved use of injectable peptides, citing potential dangers and unknown toxicity profiles associated with these substances.

Ars Technica - The advocacy for these peptides is based on their potential benefits, despite previous safety concerns that led to their ban.

HOW:

The Guardian - Dr. Michael Bonning emphasized that claims of benefits from these peptides are “seriously and significantly” overblown and cannot be supported by evidence, as most have not been clinically trialed.

Gizmodo - The process involves the FDA reviewing the safety and efficacy of the peptides to determine if they can be unbanned for production.

(UPDATED April 1, 2026 01:23 UTC)

Robert F. Kennedy Jr. announced he will approve the sale of approximately 14 injectable peptide drugs to the public. However, experts are warning against their unapproved use, highlighting potential dangers and unknown toxicity profiles. Dr. Michael Bonning added that the claims of benefits from these peptides are “seriously and significantly” overblown and lack evidence, as most have not undergone clinical trials.

--

(UPDATED March 31, 2026 23:09 UTC)

Robert F. Kennedy Jr. is advocating for the use of certain peptides, as the FDA is reportedly planning to allow the production of 14 previously banned peptides. More than a dozen of these substances are expected to be removed from a prohibition list that currently restricts compounding pharmacies from producing them, with a decision anticipated in 2026. This push for the peptides is based on their potential benefits, despite earlier safety concerns that led to their ban, and the FDA is reviewing their safety and efficacy to determine if they can be unbanned for production.